We are live on ! Find out more
RLMD icon

Relmada Therapeutics
RLMD

45 hedge funds and large institutions have $265M invested in Relmada Therapeutics in 2019 Q4 according to their latest regulatory filings, with 45 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

42,500% more call options, than puts

Call options by funds: $2.13M | Put options by funds: $5K

47.8% more ownership

Funds ownership: 0% → 47.8% (+48%)

Holders
45
Holders Change
+45
Holders Change %
–
% of All Funds
0.89%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.04%
New
45
Increased
–
Reduced
–
Closed
–
Calls
$2.13M
Puts
$5K
Net Calls
+$2.13M
Net Calls Change
+$2.13M

Top Buyers

1
TCM
Tang Capital Management
California
+$39.5M
2
VMI
VHCP Management III
New York
+$23.3M
3
RCM
RA Capital Management
Massachusetts
+$23.1M
4
RI
RTW Investments
New York
+$20.2M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$17.3M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
TCM
1
Tang Capital Management
California
$50.7M +$39.5M +1,300,000 New
VMI
2
VHCP Management III
New York
$29.9M +$23.3M +767,938 New
RCM
3
RA Capital Management
Massachusetts
$29.7M +$23.1M +761,666 New
RI
4
RTW Investments
New York
$25.9M +$20.2M +664,484 New
Vanguard Group
5
Vanguard Group
Pennsylvania
$22.2M +$17.3M +569,753 New
PCM
6
Parsons Capital Management
Rhode Island
$14.3M +$11.1M +366,933 New
BC
7
Boxer Capital
California
$11.7M +$9.12M +300,000 New
TA
8
Tiedemann Advisors
New York
$11M +$8.59M +282,592 New
Invesco
9
Invesco
Georgia
$10.5M +$8.18M +269,237 New
Franklin Resources
10
Franklin Resources
California
$8.78M +$6.84M +225,000 New
BC
11
Broadfin Capital
New York
$8.61M +$6.71M +220,724 New
BlackRock
12
BlackRock
New York
$5.58M +$4.35M +143,113 New
Point72 Asset Management
13
Point72 Asset Management
Connecticut
$5.34M +$4.16M +136,900 New
T. Rowe Price Associates
14
T. Rowe Price Associates
Maryland
$5.05M +$3.93M +129,461 New
VMI
15
VHCP Management II
New York
$4.48M +$3.49M +114,876 New
Bank of New York Mellon
16
Bank of New York Mellon
New York
$4M +$3.12M +102,614 New
Geode Capital Management
17
Geode Capital Management
Massachusetts
$3.79M +$2.95M +97,108 New
Citadel Advisors
18
Citadel Advisors
Florida
$3.13M +$2.44M +80,166 New
Charles Schwab
19
Charles Schwab
California
$1.92M +$1.49M +49,187 New
MHC
20
Meyer Handelman Company
New York
$1.19M +$923K +30,378 New
Northern Trust
21
Northern Trust
Illinois
$947K +$738K +24,281 New
Millennium Management
22
Millennium Management
New York
$905K +$705K +23,201 New
Susquehanna International Group
23
Susquehanna International Group
Pennsylvania
$686K +$535K +17,599 New
WMSA
24
Weiss Multi-Strategy Advisers
New York
$507K +$395K +13,000 New
WIA
25
World Investment Advisors
California
$507K +$395K +13,000 New
1
2

RLMD Hedge Fund Activity: Q4 2019 in Review

45 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q4 2019, worth a combined $265M.

Buyers outnumbered sellers: 45 funds opened new RLMD positions and 0 closed out — a net gain of 45 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Tang Capital Management, opening a new position worth an estimated $39.5M.

  • 45 institutional investors held Relmada Therapeutics (RLMD) as of Q4 2019, up from 0 in Q3 2019.
  • Funds reported $265M of Relmada Therapeutics stock for Q4 2019.
  • 45 funds opened new Relmada Therapeutics positions in Q4 2019 and 0 closed out, a net change of +45 holders.
  • The largest Relmada Therapeutics buyer in Q4 2019 was Tang Capital Management, an estimated $39.5M added.

Based on aggregated 13F filings for Q4 2019.